Continuous ropivacaine infusion in treatment of postoperative pain in cardiac surgery.

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2009-017625-20-FI

Enrollment

Registered

2010-05-03

Start date

2010-06-22

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Research is to verify whether continuous infusion of ropivacaine reduces post-operative analgesic requirement after cardiac surgery. MedDRA version: 12.1 Level: LLT Classification code 10019316 Term: Heart valve disorders MedDRA version: 12.1 Level: LLT Classification code 10052895 Term: Coronary artery insufficiency

Interventions

Trade Name: Naropin Pharmaceutical Form: INN or Proposed INN: ROPIVACAINE HYDROCHLORIDE CAS Number: 0 Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026